The Motley Fool··Sara AppinoCytokinetics Executive Cashes In $929K Options as Cardiac Drug Launches
Cytokinetics insider Andrew Callos sold $929K in stock options weeks after FDA approval of heart drug myqorzo, reducing holdings by 23%.
CYTKFDA approvalbiotech